A major role for CD4
CD4(+) T cells
IFN-γ
chimeric antigen receptor T cells
cytokine release syndrome
lymphoma
toxicities
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
19 09 2023
19 09 2023
Historique:
received:
10
11
2022
revised:
21
04
2023
accepted:
26
07
2023
medline:
22
9
2023
pubmed:
19
8
2023
entrez:
18
8
2023
Statut:
ppublish
Résumé
Anti-CD19 chimeric antigen receptor (CAR) T cell therapy represents a breakthrough for the treatment of B cell malignancies. Yet, it can lead to severe adverse events, including cytokine release syndrome (CRS), which may require urgent clinical management. Whether interpatient variability in CAR T cell subsets contributes to CRS is unclear. Here, we show that CD4
Identifiants
pubmed: 37595589
pii: S2666-3791(23)00314-2
doi: 10.1016/j.xcrm.2023.101161
pmc: PMC10518592
pii:
doi:
Substances chimiques
Antigens, CD19
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101161Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.
Références
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
J Clin Invest. 2016 Jun 1;126(6):2123-38
pubmed: 27111235
Front Immunol. 2020 Aug 28;11:1973
pubmed: 32983132
Mol Ther Oncolytics. 2020 Apr 14;17:278-292
pubmed: 32368616
Nat Rev Immunol. 2022 Feb;22(2):85-96
pubmed: 34002066
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Blood. 2016 Jun 30;127(26):3321-30
pubmed: 27207799
Nat Med. 2018 Jun;24(6):739-748
pubmed: 29808007
Cancer Discov. 2021 Sep;11(9):2248-2265
pubmed: 33837065
Nat Med. 2020 Dec;26(12):1878-1887
pubmed: 33020644
Nat Cancer. 2023 Jul;4(7):968-983
pubmed: 37248395
Sci Immunol. 2021 Mar 26;6(57):
pubmed: 33771887
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
J Clin Invest. 2022 Jun 15;132(12):
pubmed: 35503659
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
J Immunol. 2014 Apr 15;192(8):3654-65
pubmed: 24623129
Nat Med. 2018 Jun;24(6):731-738
pubmed: 29808005
Leukemia. 2016 Feb;30(2):492-500
pubmed: 26369987
Blood. 2017 Nov 23;130(21):2295-2306
pubmed: 28924019
Am J Hematol. 2019 May;94(S1):S42-S49
pubmed: 30784102
Blood Cancer Discov. 2022 Mar 01;3(2):136-153
pubmed: 35015685
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
J Clin Invest. 2020 Oct 1;130(10):5425-5443
pubmed: 32925169
Blood. 2012 Mar 22;119(12):2709-20
pubmed: 22160384
Blood Adv. 2021 Mar 23;5(6):1695-1705
pubmed: 33720336
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
J Cereb Blood Flow Metab. 2000 Feb;20(2):381-6
pubmed: 10698076
J Cereb Blood Flow Metab. 2008 Aug;28(8):1449-59
pubmed: 18446168
J Immunother Cancer. 2023 Jan;11(1):
pubmed: 36593069